It appeared that tumor sites with positive staining of EGFR were comparable between the vehicle and pembrolizumab groups, while EGFR+ sites were less abundant in amivantamab and combination treated groups (Fig. 4G). The gene discussed is EGFR; the disease is neoplasm.